Sanofi (SNYNF) said new data from the HARMONIE Phase 3b trial showed an 83.21% reduction in hospitalizations due to RSV-related lower respiratory tract disease in infants under 12 months of age who received a single dose of nirsevimab, compared to infants who received no RSV intervention. Throughout HARMONIE, nirsevimab maintained a favorable safety profile, the company noted.
The data also showed that nirsevimab reduced the incidence of hospitalizations due to severe RSV-related LRTD by 75.71%.
The trial included more than 8,000 infants and took place at nearly 250 sites across France, Germany and the United Kingdom.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.